ALEXION - Geography + Label Expansion = Long Term Growth

July 2011 | 4 pages | ID: A075C36136EEN
MP Advisors

Abstracts

We expect Soliris (L, Paroxysmal Nocturnal Hemoglobinuria, PNH) sales to remain on a growth trajectory due to geographical expansion and approval into other niche indications. In light of 2Q11 earning release and advancement of various R&D programs, we have analyzed Alexion (ALXN) future prospects. Full details are highlighted in the report, released on July 26, 2011, titled “Geography + Label Expansion = Long Term Growth”.

Contents

COMPANIES MENTIONED

ALEXION